|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Gastric Cancer
Cancer that forms in tissues lining the stomach. Also referred to as stomach cancer.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Advanced Gastric Cancer Study - R2301
The purpose of this randomized, double-blind, multi-center, phase III study is to assess the safety and efficacy of a Novartis investigational drug in patients with advanced gastric cancer which has progressed after one or two lines of prior chemotherapy. An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 3 Participation Duration: All patients will take two 5mg tablets of an investigative drug or matching placebo once daily in the morning. There is no set number of days for participation duration. Instead, patients will be treated with study drug until disease progression, unacceptable toxicity, or until the patient withdraws consent. Protocol Number: CRAD001R2301 |